Loading...
XHKG
2252
Market cap3.24bUSD
Jul 10, Last price  
25.32HKD
1D
2.10%
1Q
-11.16%
Name

MicroPort MedBot Shanghai Co Ltd

Chart & Performance

D1W1MN
XHKG:2252 chart
P/E
P/S
40.76
EPS
Div Yield, %
Shrs. gr., 5y
1.40%
Rev. gr., 5y
%
Revenues
551m
+114.22%
002,150,00021,603,000104,592,000257,249,000551,069,000
Net income
-250m
L-61.14%
-70,321,000-208,874,000-582,921,000-1,139,806,000-1,012,174,000-642,406,000-249,660,000
CFO
-36m
L-87.82%
-48,696,000-103,042,000-540,486,000-898,475,000-567,843,000-298,124,000-36,299,565

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.
IPO date
Employees
900
Domiciled in
CN
Incorporated in

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT